242 related articles for article (PubMed ID: 20379859)
41. Atypical radiological findings of primary central nervous system lymphoma.
Lin X; Khan IRA; Seet YHC; Lee HY; Yu WY
Neuroradiology; 2020 Jun; 62(6):669-676. PubMed ID: 32077984
[TBL] [Abstract][Full Text] [Related]
42. Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma.
Karantanis D; O'Neill BP; Subramaniam RM; Peller PJ; Witte RJ; Mullan BP; Wiseman GA
Clin Nucl Med; 2007 Apr; 32(4):271-4. PubMed ID: 17413571
[TBL] [Abstract][Full Text] [Related]
43. Can morphological MRI differentiate between primary central nervous system lymphoma and glioblastoma?
Malikova H; Koubska E; Weichet J; Klener J; Rulseh A; Liscak R; Vojtech Z
Cancer Imaging; 2016 Nov; 16(1):40. PubMed ID: 27894359
[TBL] [Abstract][Full Text] [Related]
44. Usefulness of 18F-fluorodeoxyglucose-Positron Emission Tomography in Comparison with Methionine-Positron Emission Tomography in Differentiating Solid Hemangioblastoma from Adult Cerebellar Tumors.
Takahashi Y; Nishio A; Yamamoto D; Kamada H; Hashimoto N
World Neurosurg; 2018 Feb; 110():e648-e652. PubMed ID: 29162527
[TBL] [Abstract][Full Text] [Related]
45. Differentiation of high-grade glioma and primary central nervous system lymphoma: Multiparametric imaging of the enhancing tumor and peritumoral regions based on hybrid
Zhang S; Wang J; Wang K; Li X; Zhao X; Chen Q; Zhang W; Ai L
Eur J Radiol; 2022 May; 150():110235. PubMed ID: 35290912
[TBL] [Abstract][Full Text] [Related]
46. (11)C-methionine PET/CT and MRI of primary central nervous system diffuse large B-cell lymphoma before and after high-dose methotrexate.
Jang SJ; Lee KH; Lee JY; Choi JY; Kim BT; Kim SJ; Kim WS
Clin Nucl Med; 2012 Oct; 37(10):e241-4. PubMed ID: 22955084
[TBL] [Abstract][Full Text] [Related]
47. Measurement of apparent diffusion coefficient with simultaneous MR/positron emission tomography in patients with peritoneal carcinomatosis: comparison with 18F-FDG-PET.
Schwenzer NF; Schmidt H; Gatidis S; Brendle C; Müller M; Königsrainer I; Claussen CD; Pfannenberg AC; Schraml C
J Magn Reson Imaging; 2014 Nov; 40(5):1121-8. PubMed ID: 24923481
[TBL] [Abstract][Full Text] [Related]
48. PET findings in lymphomatosis and gliomatosis of the brain: a comparison of C-11 methionine PET/CT and F-18 FDG PET/CT.
Tomura N; Saginoya T; Goto H
Acta Radiol; 2021 Oct; 62(10):1391-1396. PubMed ID: 33081486
[TBL] [Abstract][Full Text] [Related]
49. Hypermetabolic change as a possible predictive sign of a relapsed central nervous system lymphoma.
Nakahara T; Takagi Y; Shiga H; Uchida H; Kaburaki J; Kubo A
Clin Nucl Med; 2007 Feb; 32(2):87-9. PubMed ID: 17242558
[TBL] [Abstract][Full Text] [Related]
50. Differentiation between primary CNS lymphoma and glioblastoma: qualitative and quantitative analysis using arterial spin labeling MR imaging.
You SH; Yun TJ; Choi HJ; Yoo RE; Kang KM; Choi SH; Kim JH; Sohn CH
Eur Radiol; 2018 Sep; 28(9):3801-3810. PubMed ID: 29619520
[TBL] [Abstract][Full Text] [Related]
51. Diagnostic value of kinetic analysis using dynamic FDG PET in immunocompetent patients with primary CNS lymphoma.
Nishiyama Y; Yamamoto Y; Monden T; Sasakawa Y; Kawai N; Satoh K; Ohkawa M
Eur J Nucl Med Mol Imaging; 2007 Jan; 34(1):78-86. PubMed ID: 16896670
[TBL] [Abstract][Full Text] [Related]
52. The Multiple Faces of Nervous System Lymphoma. Atypical Magnetic Resonance Imaging Features and Contribution of the Advanced Imaging.
Jiménez de la Peña MD; Vicente LG; Alonso RC; Cabero SF; Suárez AM; de Vega VM
Curr Probl Diagn Radiol; 2017; 46(2):136-145. PubMed ID: 27475832
[TBL] [Abstract][Full Text] [Related]
53. Comparison of MR imaging and FDG-PET/CT in the differential diagnosis of benign and malignant vertebral compression fractures.
Cho WI; Chang UK
J Neurosurg Spine; 2011 Feb; 14(2):177-83. PubMed ID: 21214309
[TBL] [Abstract][Full Text] [Related]
54. New MR perfusion features in primary central nervous system lymphomas: pattern and prognostic impact.
Blasel S; Vorwerk R; Kiyose M; Mittelbronn M; Brunnberg U; Ackermann H; Voss M; Harter PN; Hattingen E
J Neurol; 2018 Mar; 265(3):647-658. PubMed ID: 29383512
[TBL] [Abstract][Full Text] [Related]
55. Clinical interest of integrating positron emission tomography imaging in the workup of 55 children with incidentally diagnosed brain lesions.
Pirotte BJ; Lubansu A; Massager N; Wikler D; Van Bogaert P; Levivier M; Brotchi J; Goldman S
J Neurosurg Pediatr; 2010 May; 5(5):479-85. PubMed ID: 20433262
[TBL] [Abstract][Full Text] [Related]
56. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
57. Fluorodeoxyglucose positron emission tomography (FDG-PET) and PET/computed tomography imaging characteristics of thyroid lymphoma and their potential clinical utility.
Basu S; Li G; Bural G; Alavi A
Acta Radiol; 2009 Mar; 50(2):201-4. PubMed ID: 19089692
[TBL] [Abstract][Full Text] [Related]
58. Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging.
Kickingereder P; Wiestler B; Sahm F; Heiland S; Roethke M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
Radiology; 2014 Sep; 272(3):843-50. PubMed ID: 24814181
[TBL] [Abstract][Full Text] [Related]
59. Optimization of semi-quantification in metabolic PET studies with 18F-fluorodeoxyglucose and 11C-methionine in the determination of malignancy of gliomas.
Borbély K; Nyáry I; Tóth M; Ericson K; Gulyás B
J Neurol Sci; 2006 Jul; 246(1-2):85-94. PubMed ID: 16603193
[TBL] [Abstract][Full Text] [Related]
60. 18F-FDG PET/MR for diagnosis of primary central nervous system lymphoma: protocol for a systematic review and meta-analysis.
Qiu X; Zheng H; Zhong F; Shen B
BMJ Open; 2024 May; 14(5):e081458. PubMed ID: 38806425
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
